# A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2

Source: https://onco.cc/trials/nct07203053/  
OnCo record `nct07203053` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of tarlatamab in lung cancer, run by ETOP IBCSG Partners Foundation, now recruiting.

## Summary

A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 is a phase 2, interventional study registered as NCT07203053 by ETOP IBCSG Partners Foundation, with a registry enrolment figure of 48 participants, started 2026-04-15 and due to reach its primary completion in 2029-10. Interventions recorded: Tarlatamab. Conditions listed: Extensive Stage Lung Small Cell Cancer. Primary outcome: Overall survival rate at 12 months (12-month OS). Lung eligibility wording from the registry: "* Histologically or cytologically confirmed ES-SCLC". Sites: France, Greece, Italy, Spain, Switzerland. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: START-lung
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07203053
- Phase: 2
- Setting: A Multicentre Phase II Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
- Sponsor: ETOP IBCSG Partners Foundation
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT07203053: https://clinicaltrials.gov/study/NCT07203053

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- drugs: [Tarlatamab](https://onco.cc/drugs/tarlatamab/)
- companies: [Amgen](https://onco.cc/companies/amgen/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07203053.json